Latest & Greatest

Latest & Greatest

Recent developments in the field of hematology/oncology, including drug approvals, policy updates, and clinical trial results

FDA Approvals, Draft Guidance on Biosimilar Naming, House Bill on Stem Cell Research, and...

FDA Expands Eltrombopag Indication to Even Younger Pediatric Patients with ITP The U.S. Food and Drug Administration (FDA) expanded the indication for eltrombopag for the...

FDA Approves Carfilzomib, Court Rules on Off-Label Drug Use, ABIM Reform, and more

FDA Approves Carfilzomib for Second-Line Multiple Myeloma The U.S. FDA has approved expanded use of carfilzomib for the treatment of multiple myeloma when used in...

Supreme Court Rules on ACA, CMS Updates Medicare Physician Fee Schedule, and more

Supreme Court Votes to Uphold Tax Subsidies Under the Affordable Care Act In a 6-3 ruling, the Supreme Court voted to uphold the tax subsidies outlined...

Viral History from a Single Drop of Blood, NCI Launches Gene Therapy Trial, FDA...

Going Viral: A New Test Detects Lifetime Virus Exposure with a Single Drop of Blood VirScan, a recently developed, high-throughput blood test, can detect nearly...

FDA to Lift Ban on Blood Donations from Gay Men, the House Approves the...

FDA Plans to Lift Ban on Blood Donations from Gay Men In 1983, shortly after the onset of the AIDS epidemic, the U.S. Food and...

NOAC Reversal Agent Granted Priority Review, New Drug for Rare Type of Leukemia, and...

Dabigatran Reversal Agent Idarucizumab Granted Priority Review by the FDA The U.S. Food and Drug Administration has granted priority review to the biologics license application...

Carfilzomib in Multiple Myeloma, New FDA App to Track Drug Shortages, and more

Carfilzomib Granted Priority Review in Relapsed Multiple Myeloma The U.S. Food and Drug Administration granted priority review status to the supplemental new drug application for...

FDA Approves First Biosimilar Drug, New Indication for Lenalidomide, and more

FDA Approves First Biosimilar Drug Zarxio (filgrastim-sndz), a biosimilar product of filgrastim, was recently approved by the U.S. Food and Drug Administration (FDA). This is...

FDA Expands Use of Ibrutinib, Fast Track Designation Granted to SGX301, and more

FDA Expands Use  of Ibrutinib for Waldenström Macroglobulinemia The U.S. Food and Drug Administration (FDA) approved the expanded use of ibrutinib to treat Waldenström macroglobulinemia (WM),...

Making Blood Transfusions Safer, New Indication for Ruxolitinib, and more

FDA Approves System to Make Blood Transfusions Safer The U.S. Food and Drug Administration (FDA) approved the Intercept Blood System, a new system designed to...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.